Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will significantly enhance the patent protection of its lead compound SCO-101 in the important US market. Scandion has received a Notice of Allowance from the United States Patent and Trademark Office meaning a patent will officially be granted following payment of the issue fee, which will be done shortly.

The patent will cover methods of using SCO-101 and any other so-called VRAC modulator to sensitize cancer cells to any anti-cancer agent or potentiate the therapeutic effect of any anti-cancer agent. The patented methods will cover treatment of a comprehensive range of specific cancers, including colorectal and pancreatic cancer, regardless of whether the cancers are resistant to current treatments or not. Thus, the patent offers a very broad intellectual protection until at least 2037, which will allow Scandion to potentially target also earlier lines of treatment.

When granted, the patent will enhance Scandion’s existing patent exclusivity on SCO-101 in the US, which currently includes a patent on combination therapy of resistant cancers. The patent protection of SCO-101 was already recently significantly strengthened by the granting of a new Composition-of-Matter patent by the European Patent Office in November 2023.

“We are delighted to receive this Notice of Allowance allowing us to further strengthen our intellectual property rights. As an innovative company, we rely on solid patent protection of our discoveries and molecules. This is not least important in the US, which is the world’s biggest pharmaceutical market, so this new US patent will be an important value driver for Scandion”, says Francois Martelet, CEO of Scandion.

SCO-101 is currently being clinically developed as a combination treatment for metastatic colorectal cancer and pancreatic cancer.

Scandion believes that SCO-101 can revert cancer’s resistance to treatments like chemotherapy thereby making the treatments work better and longer. Today, cancer drug resistance continues to constitute a huge unmet medical need.

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: [email protected]

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on January 5, 2024, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.